S. 2211: Special Diabetes Program Reauthorization Act of 2025

The bill titled the Special Diabetes Program Reauthorization Act of 2025 aims to reauthorize and extend funding for two specific diabetes programs: one focused on Type 1 diabetes and the other on assisting American Indians affected by diabetes. Below is a breakdown of the key components of the bill:

Funding for Type 1 Diabetes Programs

The legislation proposes amending existing provisions within the Public Health Service Act related to the Special Diabetes Program for Type 1 Diabetes. Key points include:

• Authorization of $160 million for each of the fiscal years 2026 and 2027 to support initiatives related to Type 1 diabetes.
• In addition, $40 million would be authorized for a specific period starting on October 1, 2027, and ending on December 31, 2027.
• The funds will remain available until they are fully expended, allowing for flexibility in program implementation.

Funding for Diabetes Programs for Indians

Similar to the approach for Type 1 diabetes, the bill also proposes changes to the funding structure for the Special Diabetes Program for Indians. This includes:

• Authorization of $160 million for the fiscal years 2026 and 2027 to support diabetes prevention and treatment initiatives in Indian communities.
• Authorization of $40 million for the timeframe starting October 1, 2027, and ending December 31, 2027.
• These funds will also be available until expended, ensuring that the programs have necessary financial support over the specified period.

Overall Objectives

The main objective of the bill is to ensure continued federal support for diabetes management programs targeting Type 1 diabetes and indigenous populations, providing essential funding to improve health outcomes and support research and prevention initiatives.

Relevant Companies

• MDLZ (Mondelez International, Inc.): Potentially impacted due to their portfolio in health-focused products that may see increased demand as diabetes management becomes a priority.
• ABBV (AbbVie Inc.): May benefit from increased attention to diabetes treatments as funding potentially flows into research for diabetes medications.